Van lent Pharma SRL
Van lent Pharma reported total assets of 96,286 € at the end of the 2025 financial year (annual accounts filed with the NBB on 15 Jul 2026).
The score of Van lent Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +95 % Total assets +51 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Van lent Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 15 Jul 2026
- Year ended 31 Dec 2024filed on 02 Jul 2025
- Year ended 31 Dec 2023filed on 17 Jun 2024
- Year ended 31 Dec 2022filed on 08 Jun 2023
Van lent Pharma's financial analysis
- Solvency85.7%sector median: 55.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Van lent Pharma
Van lent Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0774.450.473
- VAT number
- BE0774450473
- Peppol
- Registered · 0208:0774450473 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 Sep 2021
- Registered office
- 2880 Bornem
- Latest accounts
- 2025 · filed on 15 Jul 2026
- Activity
- Other business support service activities n.e.c. (NACE 82990)
Van lent Pharma (SRL) has been based in Bornem since 2021, active in: other business support service activities n.e.c.. For 2025, it reports a net profit of 80,052 € and equity of 82,552 €; its revenue is not published. Its solvency stands at 85.7%, above the median of its sector (55.4%).
Companies similar to Van lent Pharma
Companies in the same business, of comparable size and area, outside its group.
- CMO Consult Other business support service activities n.e.c. Zaventem · balance sheet 96,193 €
- Rocon Other business support service activities n.e.c. Antwerp · balance sheet 96,108 €
- Nipa Consult Other business support service activities n.e.c. Uccle · balance sheet 96,484 €
- Peter Verpoort Consulting Other business support service activities n.e.c. Kontich · balance sheet 95,997 €
- THE Real Deal Other business support service activities n.e.c. Ghent · balance sheet 95,996 €
- Apotheek Robert VAN Praet Other business support service activities n.e.c. Koksijde · balance sheet 96,714 €
- RK Consulting Other business support service activities n.e.c. Mechelen · balance sheet 96,786 €
- C&C Fexer Other business support service activities n.e.c. Antwerp · balance sheet 96,829 €
Frequently asked questions about Van lent Pharma
What is the revenue of Van lent Pharma?
Van lent Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Van lent Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0774450473 for Van lent Pharma, if the company is VAT-registered. Its company number (CBE) is 0774.450.473.
Where is the registered office of Van lent Pharma?
According to the CBE register, the registered office of Van lent Pharma is in 2880 Bornem.
What is the equity of Van lent Pharma?
At the close of the 2025 financial year, the equity of Van lent Pharma amounts to 82,552 €, a solvency of 85.7% of total assets.
Who manages Van lent Pharma?
The register lists 1 active mandates at Van lent Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Van lent Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →